Rhythm Pharmaceuticals met phase 3 endpoint for treating hypothalamic obesity, with regulatory submissions planned for 2025.

Based on our established INTRABEAM platform, the newly developed ZEISS INTRABEAM 700 marks the next major step on our path to ...

Find investment ideas for your portfolio with the latest stock picks from Barron’s below ... based on original reporting and data analysis, free from conflicts of interest ...